<DOC>
	<DOCNO>NCT01209156</DOCNO>
	<brief_summary>The underlying goal study assess PBR-111 positron emission tomography ( PET ) image tool detect microglial activation brain Alzheimer disease ( AD ) research participant age- gender-matched healthy volunteer .</brief_summary>
	<brief_title>Evaluation 18F PBR111 PET Marker Inflammation Subjects With Neurological Conditions</brief_title>
	<detailed_description>This phase 1 , open-label , single-center , non-randomized single dose study ass kinetics , clearance cerebral distribution PBR-111 positron emission tomography ( PET ) image detect microglial activation brain patient probable Alzheimer disease ( AD ) compare healthy volunteer ( HVs ) . All aspect relate image acquisition , process visual well quantitative evaluation develop , optimize validate ( require ) . Each subject require visit study center screen phase PBR-111 PET image day ( baseline ) . A telephone follow-up visit perform 7 day ( +/- 3 day ) PBR-111 PET administration . At screen visit , subject ( caregiver case AD subject ) ask provide write informed consent assent . During screen phase ( maximum duration - 60 day ) subject medical , neurological surgical history , clinical assessment neuro-psychiatric evaluation perform eligible subject . Subjects allow leave center evaluation complete . During period MRI brain perform . During PBR-111 PET image day , subject receive single IV injection PBR-111 scanning perform 3.5 hour period . Each subject telephone follow-up 7 day ( +/- 3 day ) thereafter assess adverse event .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Alzheimer Disease ( AD ) 1 . The participant 50 year old . 2 . Written inform consent obtain . 3 . Participants clinical diagnosis probable Alzheimer disease base National Institute Neurological Communicative Disorders Stroke/Alzheimer Disease Related Disorders Association ( NINCDS/ADRDA ) criterion . 4 . Does fulfill ICC criterion probable DLB ( Appendix 3 ) , NINDSAIREN probable Vascular dementia ( Appendix 5 ) , Neary [ Neary et al . 1998 ] criterion FTD ( Appendix 4 ) 5 . Clinical Dementia Rating Scale score ≤ 2 . 6 . Modified Hachinski Ischemia Scale score ≤ 4 . 7 . MRI brain scan finding reveal change indicative stroke and/or generalize cerebrovascular disease ( e.g. , ARWMC scale ) change limit : white matter lesion score 0 1 2 basal ganglion score 0 1 ) 8. caregiver willing able attend study visit perform psychometric test require presence caregiver 9 . For female , nonchild bear potential negative urine blood pregnancy test day [ 18F ] PBR111 injection . EXCLUSION CRITERIA : Alzheimer Disease ( AD ) 1 . History significant cerebrovascular disease . 2 . Clinically significant abnormal laboratory value and/or clinically significant unstable medical psychiatric illness 3 . Evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , neurological , immunodeficiency , pulmonary , disorder disease . 4 . Pregnancy 5 . Contraindication MRI examination , e.g . metal implant phobia determine onsite radiologist perform scan 6 . History exposure radiation &gt; 15 mSv/year ( e.g . occupational radiation therapy ) 7 . Receiving drug therapy treatment know lead greatly fluctuate value hematological chemical laboratory parameter severe side effect ( e.g . chemotherapy ) 8 . Received antiamyloid drug therapy . INCLUSION CRITERIA : Healthy Volunteer ( HV ) 1 . The participant 18 year old , least 4 subject ≥50 year . 2 . Written inform consent obtain . 3 . Negative history neurological psychiatric illness base evaluation research physician . 4 . Has evidence cognitive impairment indicate clinical dementia rating ( CDR , [ Hughes et al . 1993 ] ) score 0 ( zero ) score ≥ 28 MiniMental Status Examination ( MMSE , [ Folstein et al . 1975 ] ) Clinical Dementia Rating score = 0 . 5. MRI brain scan judge `` normal ( age appropriate ) '' include ARWMC scale [ Wahlund et al . 2001 ] score support lack cerebrovascular disease ( e.g. , white matter lesion score 0 1 2 basal ganglion score 0 1 ) Scheltens scale [ Scheltens et al . 1992 ] verify lack cerebral atrophy ( e.g . bilateral temporal lobe atrophy visual score 0 1 ) 6 . For female , nonchild bear potential negative urine blood pregnancy test day [ 18F ] PBR111 injection . EXCLUSION CRITERIA : Healthy Volunteer ( HV ) 1 . History significant cerebrovascular disease . 2 . Clinically significant abnormal laboratory value and/or clinically significant unstable medical psychiatric illness 3 . Evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , neurological , immunodeficiency , pulmonary , disorder disease . 4 . Pregnancy 5 . Contraindication MRI examination , e.g . metal implant phobia determine onsite radiologist perform scan 6 . History exposure radiation &gt; 15 mSv/year ( e.g . occupational radiation therapy ) 7 . Receiving drug therapy treatment know lead greatly fluctuate value hematological chemical laboratory parameter severe side effect ( e.g . chemotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>